IBRXImmunityBio, Inc.

$8B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165,000+3200.0% YoY

Gross Profit

$165,000100.0% margin

Operating Income

-$37M-22243.6% margin

Net Income

-$37M-22447.3% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-82.1%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$480,000

Balance Sheet

Total Assets

$127M

Total Liabilities

$24M

Stockholders' Equity

$103M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165,000	$5,000	+3200.0%
Gross Profit	$165,000	$5,000	+3200.0%
Operating Income	-$37M	-$18M	-104.8%
Net Income	-$37M	-$18M	-107.1%

IBRX Q1 2020 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena